<unk>  is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name Simponi.<unk>  targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates<unk>  as an effective modulator of inflammatory markers and bone metabolism. It is on the World Health Organization's List of Essential Medicines.<unk>  was developed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) which also markets the product in the United States. The Janssen Pharmaceutical Companies market Simponi in Canada, Central and South America, the Middle East, Africa and Asia Pacific. In Europe, Russia and Turkey, Simponi distribution rights are held by Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. In Japan, Indonesia and Taiwan, distribution rights are held by Mitsubishi Tanabe Pharma Corporation.
Golimumab
Belimumab
Sarilumab
Belatacept
Tofacitinib
Anifrolumab
Adalimumab
Avelumab